Quetiapine fumarate + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Borderline Personality Disorder
Conditions
Borderline Personality Disorder
Trial Timeline
Jun 1, 2004 → Jun 1, 2007
NCT ID
NCT00254748About Quetiapine fumarate + Placebo
Quetiapine fumarate + Placebo is a phase 2 stage product being developed by AstraZeneca for Borderline Personality Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00254748. Target conditions include Borderline Personality Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00254748 | Phase 2 | Completed |
Competing Products
12 competing products in Borderline Personality Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine + placebo | Eli Lilly | Phase 3 | 77 |
| olanzapine | Eli Lilly | Pre-clinical | 23 |
| Olanzapine | Eli Lilly | Phase 3 | 77 |
| Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Durvalumab + Tremelimumab + Gemcitabine + Cisplatin | AstraZeneca | Phase 2 | 52 |
| quetiapine extended-release + Placebo | AstraZeneca | Phase 3 | 77 |
| Quetiapine Fumarate | AstraZeneca | Phase 3 | 77 |
| ziprasidone + Placebo | Pfizer | Phase 2 | 51 |
| Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin | Bristol Myers Squibb | Phase 1 | 32 |
| PD-1/PD-L1 inhibitors + Chemotherapy | BeOne Medicines | Phase 2 | 49 |
| Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab | Arcus Biosciences | Phase 1/2 | 36 |
| vafidemstat + Placebo | Oryzon Genomics | Phase 2 | 44 |